3billion Starts Beta Service for Comprehensive Rare Disease Screening

4,000 rare diseases screened with one simple test. Close beta service with 100 pre-selected patients. Open beta service expected to launch in May.

Seoul, Korea, South, February 18, 2017 --(PR.com)-- 3billion is starting its close beta rare disease screening service with 100 pre-selected patients. Using whole exome and genome analysis, 3billion screens for over 4,000 rare diseases at once from patient’s saliva sample. A patient can easily order this screening service through 3billion’s website (https://3billiion.io) and receive the results in about 8 weeks. As direct to patient service, 3billion screens for presence of any mutations that are associated with all classified rare diseases.

While each rare disease is rare on its own, more than 7,000 rare disease have been identified. Statistically, 1 out of 10 people suffer from a rare disease in the United States alone, and more than 350 million patients, 1 out of 20, suffer from a rare disease globally (report.nih.gov/nihfactsheets/ViewFactSheet.aspx).

Since 80% of rare diseases have a genetic origin, genome analysis could provide a valuable insight to each condition (report.nih.gov/nihfactsheets/ViewFactSheet.aspx). However, most of the rare disease patients do not have access to this technology due to limited insurance coverage and expensive price. To address this problem, 3billion is the first in the world to provide affordable rare disease screening through direct to patient business model.

Starting this month, 3billion will work with 100 pre-selected rare disease patients for closed beta testing. For any patients who were not included in close beta testing, they can sign up for open beta testing through 3billion’s website (http://3billion.io). Patients who sign up early will receive special discount when the open beta starts in May 2017.

3billion’s CEO ChangWon Keum said, “Genome analysis technology is still not accessible to most patients due to the expensive price tag and limited analysis capabilities. 3billion is the first in the world to provide rare disease specific genome analysis service directly to the patients. We provide a streamlined process from sample collection to data analysis. We hope to empower many rare disease patients through our screening service.”

About 3billion
3billion provides comprehensive rare disease screening service directly to patients who are looking for answers. As a spinoff company of Macrogen, 3billion uses whole exome and genome sequencing technology to screen for over 4,000 rare diseases at once. 3billion’s rare disease screening service is currently going through beta testing and will officially launch at the end of 2017. To learn more visit http://3billion.io.
Doohyun Park